Warning: file_put_contents(/srv/users/serverpilot/apps/bitupdateus/public/wp-content/plugins/bulk-post-0.4-1/cache/sessions//f3iTBVGMSrNynq2bQIpU4ysJeYn6ixatUNxzcMm1): failed to open stream: No space left on device in /srv/users/serverpilot/apps/bitupdateus/public/wp-content/plugins/stupidpie-1.8.3-1/vendor/illuminate/filesystem/Filesystem.php on line 122
  Euro on Sunday Stock Check: Novartis: Doctor Vas's Success Recipe | Message | Bit Updates
Home » bitcoin updates » Euro on Sunday Stock Check: Novartis: Doctor Vas's Success Recipe | Message

Euro on Sunday Stock Check: Novartis: Doctor Vas's Success Recipe | Message

Tuesday, January 30th, 2018 | bitcoin updates

by Sven Parplies, Euro on Sunday
Many at Novartis just know the new boss under the nickname Vas. The full name easily becomes the tongue twister: Vasant Narasimhan is American with Indian roots. Above all, the 41-year-old is an excellent specialist.
Among other things, the physician was responsible for the drug development of Novartis. After years of stagnation, Narasimhan is to lead the Swiss giant back on growth path. The basis for this has been laid, but there are many challenges in detail.
Predecessor Joe Jimenez says goodbye with an optimistic outlook: For the new year, he is forecasting a sales increase in the low to mid single-digit percentage range. Adjusted operating profit is expected to grow in the mid to high single-digit percentage range. That would be significant improvements and it explains the Novartis share price jump this week.
In the Pharmaceuticals division, the largest and most profitable division, Novartis is focusing on new products such as the heart medicines Entresto and Cosentyx for the treatment of psoriasis. Increases in sales there are intended to absorb declines in older products, whose patent protection has expired and are therefore being attacked by cheap generics competition. Novartis' latest figures indicate that the new drugs are strong enough.

Two patients
The two smaller divisions, on the other hand, are causing problems: Sandoz's generics business suffers from price pressure in the industry, especially in the US, where the market is contested. Narasimhan wants to focus Sandoz on products from areas where the competition is not quite as intense. Novartis has high hopes for biosimilars, ie imitations of complex drugs.
The second patient, Alcon, has been in treatment for some time – and on the road to recovery. Sales rose last year, but operating profit shrank again. At the earliest in the first half of 2019, Novartis wants to decide what exactly will become of the division. A sale or a spin-off would be conceivable.
As a dividend for the 2017 financial year, shareholders are to receive 2.80 francs for each paper. That's a premium of two percent on the previous year. With that, the series continues: Since the company was founded in 1996, Novartis has increased its dividend every year.


"The favorites ride&

According to an old market logic, the transport sector should run particularly well

Calculating cash flow for

Several factors play an important role in the consideration of investing in real

Instant Payment: Introduc

                         (Picture: dpa, Angelika Warmuth / Icon)                                            The instant

Austria: money is availab

He is not awkward, the young chancellor. Even before he announced his first